Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.
about
Studies of Immune Responses in Candida vaginitisTreatment of vaginal candidiasis for the prevention of preterm birth: a systematic review and meta-analysisInsights into the antimicrobial properties of hepcidins: advantages and drawbacks as potential therapeutic agentsThe epithelial adhesin 1 (Epa1p) from the human-pathogenic yeast Candida glabrata: structural and functional study of the carbohydrate-binding domainIn vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasisFungal Profile of Vulvovaginal Candidiasis in a Tertiary Care HospitalCandida infections of the genitourinary tract.Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077].Antifungal susceptibility patterns, in vitro production of virulence factors, and evaluation of diagnostic modalities for the speciation of pathogenic Candida from blood stream infections and vulvovaginal candidiasis.Assimilation of NAD(+) precursors in Candida glabrata.Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.UPC2A is required for high-level azole antifungal resistance in Candida glabrata.The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective.Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists aIncreased diversity of fungal flora in the vagina of patients with recurrent vaginal candidiasis and allergic rhinitis.Candida parapsilosis, an emerging fungal pathogenComparison Between Virulence Factors of Candida albicans and Non-Albicans Species of Candida Isolated from Genitourinary Tract.Host cell invasion by medically important fungiExtracellular enzymes and susceptibility to fluconazole in Candida strains isolated from patients with vaginitis and healthy individuals.Microbial colonization of irradiated pathogenic yeast to catheter surfaces: Relationship between adherence, cell surface hydrophobicity, biofilm formation and antifungal susceptibility. A scanning electron microscope analysis.Isolation of different species of Candida in patients with vulvovaginal candidiasis from sari, iran.Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.Antifungal Susceptibility Patterns of Vulvovaginal Candida species among Women Attending Antenatal Clinic at Mbarara Regional Referral Hospital, South Western Uganda.Transcriptional response of Candida parapsilosis following exposure to farnesol.A Murine Model of Candida glabrata Vaginitis Shows No Evidence of an Inflammatory Immunopathogenic Response.Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasisAntifungal Properties of Crude Extracts, Fractions, and Purified Compounds from Bark of Curatella americana L. (Dilleniaceae) against Candida SpeciesIdentification of Candida species associated with vulvovaginal candidiasis by multiplex PCR.Anticandidal immunity and vaginitis: novel opportunities for immune intervention.Comparison of the therapeutic effects of Garcin(®) and fluconazole on Candida vaginitisMiconazole: a historical perspective.Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection.Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis.Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013)Association of a variable number tandem repeat in the NLRP3 gene in women with susceptibility to RVVCHealth-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis.Antifungal resistance of Candida glabrata vaginal isolates and development of a quantitative reverse transcription-PCR-based azole susceptibility assay.Susceptibility pattern of various azoles against Candida species causing vulvovaginal candidiasisMolecular phylogenetic analysis of a geographically and temporally matched set of Candida albicans isolates from humans and nonmigratory wildlife in central Illinois.Species Distribution and In Vitro Antifungal Susceptibility of Vulvovaginal Candida Isolates in China.
P2860
Q26782272-04A0B33A-D2C9-4085-9C55-6F31C267E8B5Q26864461-E68587E8-2929-48DA-8068-A5707A8963BFQ26991996-B8D1B281-8B4C-4845-88E3-2DCE572E6261Q27677360-06ECD6FF-B133-407E-8895-8F94287884C3Q33589734-610BD774-5D9C-424E-AB35-DB82AF3B98FAQ33666272-DF63B47B-5AFA-42A6-820F-895FFDE952E8Q33825621-DD58CB9B-23C6-4432-82B3-1FF6520759DEQ33843884-D2B772E1-9939-4110-869A-3CE55CD232B5Q33993054-3BE58C6F-3357-4092-BA41-E1AEF4AE14F3Q34006001-E8363560-DE7C-4612-BC92-02FD35DB6CC1Q34045468-B813CB7E-9028-405E-BEB7-6CE9ACBE9989Q34058180-2B091E7A-FE14-4966-8740-7225BACCD128Q34186380-5B7C6BCD-5B7A-4F1D-9F18-CA93A57F251CQ34269717-A4324B4D-7583-4F38-9B80-3DE34FBCC9F9Q34327713-F4F7DAA7-3E85-4EA2-BC4C-5F952D550FCBQ34852747-DA3769B2-94C3-4689-85DA-79A04A36CB9FQ34909936-71321974-9029-40F4-86A0-B9F42D62E233Q34930227-65DBAE50-06F9-4C92-AF21-8070DDB75213Q35276239-562B9172-A9ED-4B74-A5AE-958AC3552532Q35574796-479600DE-0939-4AC3-BD81-FDAC34E17D4CQ35667766-753AE0C9-595D-4CFD-B480-F7E2ADD512D8Q35806236-2D22EB6E-9E74-4A0A-A20E-BA265F1F5C86Q35848519-B0DC1F13-4534-447F-B158-44C15DB0241DQ35879037-718B4512-E17E-49DD-A9E6-70C1C6382B77Q35903282-E4A5192B-26AC-4F07-A3AA-2890E4E20C58Q35960896-5B872AE4-0C65-45E0-B57A-376F87D6DF1AQ35992453-A02B8A59-6926-46BB-8F2B-692E34979588Q36076036-BA0B1EAD-1273-4F4E-AAC8-3550BFFACAF6Q36097307-9EFAA121-29C6-45C6-A0E3-B4301E7A7947Q36186078-D01FBE7B-8AFD-4AA5-917D-91B98AEC629AQ36441479-C65C78D7-48E7-4FDF-A232-5ACE11D84332Q36539905-13BE0B70-92F5-4FA2-A0B0-FB3D0D57D278Q36624463-BD394C70-030D-4B70-BDD8-24000288295FQ36743194-7E2D0D7E-40F0-49A4-B7D0-A4544A305E68Q36823742-7B73BBC5-DA9F-40A4-9E21-852422D73C5EQ36850886-84319D22-4CA9-4853-B8E9-E224E3625FA6Q36870890-F9840791-FB92-4503-998F-ADBD8BD2DEA4Q36877951-10BAE256-603F-4422-BB9D-14E225A0FD5BQ36899118-F3512D5B-FCD2-43C6-A0C4-077F02518A97Q36930128-3A628F7F-7933-41D9-9ED8-3F9DA36C56C8
P2860
Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Antifungal susceptibilities of ...... idemiology of recurrent cases.
@ast
Antifungal susceptibilities of ...... idemiology of recurrent cases.
@en
type
label
Antifungal susceptibilities of ...... idemiology of recurrent cases.
@ast
Antifungal susceptibilities of ...... idemiology of recurrent cases.
@en
prefLabel
Antifungal susceptibilities of ...... idemiology of recurrent cases.
@ast
Antifungal susceptibilities of ...... idemiology of recurrent cases.
@en
P2093
P2860
P50
P1476
Antifungal susceptibilities of ...... idemiology of recurrent cases.
@en
P2093
Richard J Hollis
Rudolph P Galask
Sandra S Richter
P2860
P304
P356
10.1128/JCM.43.5.2155-2162.2005
P407
P577
2005-05-01T00:00:00Z